Ribociclib and Spartalizumab in R/M HNSCC
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: single arm, phase I study with dose titration plan.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 20 years and 70 years
- Gender
- Both males and females
Description
The study is a phase I study testing ribociclib (with dose titration plan) and spartalizumab (fixed dose) for R/M HNSCC. The primary endpoints are safety and objective response rate.
The study is a phase I study testing ribociclib (with dose titration plan) and spartalizumab (fixed dose) for R/M HNSCC. The primary endpoints are safety and objective response rate.
Tracking Information
- NCT #
- NCT04213404
- Collaborators
- Novartis
- Investigators
- Principal Investigator: Hsiang-Fong Kao, MD National Taiwan University Hospital
Get Well Soon